Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Trial Profile

Pilot Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2018

At a glance

  • Drugs Hyaluronidase (Primary) ; Gemcitabine; Paclitaxel; Rivaroxaban
  • Indications Adenocarcinoma; Pancreatic cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 21 Mar 2018 Planned number of patients changed from 56 to 88.
    • 20 Jan 2018 Updated safety and efficacy data will be reported in future.
    • 20 Jan 2018 Interim results (n=28) assessing safety and efficacy presented at the 2018 Gastrointestinal Cancers Symposium
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top